CN1915230A - Injection in large capacity of sodium sulfonate containing tanshinone IIA and preparation method - Google Patents
Injection in large capacity of sodium sulfonate containing tanshinone IIA and preparation method Download PDFInfo
- Publication number
- CN1915230A CN1915230A CN 200510090489 CN200510090489A CN1915230A CN 1915230 A CN1915230 A CN 1915230A CN 200510090489 CN200510090489 CN 200510090489 CN 200510090489 A CN200510090489 A CN 200510090489A CN 1915230 A CN1915230 A CN 1915230A
- Authority
- CN
- China
- Prior art keywords
- injection
- tanshinone iia
- sodium
- iia sulfate
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A high-capacity injection contains tanshinone IIA-sodium sulfonate and pharmacologically acceptable additive. Its preparing process is also disclosed.
Description
[technical field]
The invention belongs to medical technical field, relate to a kind of high-capacity injection, particularly relate to a kind of high-capacity injection that contains sodium tanshinone IIA sulfate, and the preparation method of this injection.
[background technology]
Radix Salviae Miltiorrhizae (RADIX ET RHIZOMA SALVIAE MILTIORRHIZAE) is as a kind of important Chinese crude drug, and " Chinese pharmacopoeia is recorded by many editions.Radix Salviae Miltiorrhizae is the dry root and rhizome of labiate Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bge..Spring, Qiu Erji excavate, and remove silt, and be dry and get.The Radix Salviae Miltiorrhizae hardship is slightly cold; GUIXIN, Liver Channel.Has stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, the function of the relieving restlessness that clears away heart-fire.Be used for menoxenia, amenorrhea dysmenorrhea ， lumps in the chest and abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection swells and ache, dysphoria and insomnia; Hepatosplenomegaly, diseases such as angina pectoris.Radix Salviae Miltiorrhizae is because of the difference of extracting method, and the contained main chemical compositions of Radix Salviae Miltiorrhizae mainly contains two big classes, promptly fat-soluble tanshinone compound and water-soluble phenolic acid compounds.The biological activity of this two classes chemical constituent is confirmed by many medical literature and clinical practice.Liposoluble constituent in the Radix Salviae Miltiorrhizae mainly is that a class is the tanshinone analog that contains conjugation o-quinone structure of representative with the tanshinone.Extract tanshinone from Radix Salviae Miltiorrhizae, the sterile water solution of the sodium tanshinone IIA sulfate that obtains after sulfonation has strengthened the water solublity of medicine greatly, has obtained the novel drugs of higher curative effect.
Sodium tanshinone IIA sulfate is clinical to be used for angina pectoris and myocardial infarction, cerebral arteries and arteria retina and the formation of peripheral vein thrombosis, Behcet's syndrome, erythema nodosum.
Coronary artery dilator, coronary blood flow increasing; Decreased heart rate increases myocardial contraction, improves the myocardial metabolism disorder and the cardiac function that cause after the anoxia; Anticoagulant; Promote tissue repair; Blood fat reducing; Protection erythrocyte and bacteria growing inhibiting.
At present sodium tanshinone IIA sulfate has only little aqueous injection in the dosage form of China's listing, and (product standard number: WS-10001-(HD-1014)-2002), clinical alternative dosage form is less for the loaded China national drug standard of its quality standard.
Chinese patent application (application number 200310121026.3, publication number 1555791) discloses the sodium tanshinone IIA sulfate powder needle injection, but the inventor find, adopt this patented technology to make injectable powder after, its solubility is slower, is unfavorable for clinical use.
In addition, injection with small volume after the long term store, precipitation occurs easily under cryogenic conditions, but unexpected discovery is, making the sodium tanshinone IIA sulfate high-capacity injection, particularly make sodium tanshinone IIA sulfate sodium chloride high-capacity injection after, can avoid sedimentary generation.
The inventor has successfully made the high-capacity injection that contains sodium tanshinone IIA sulfate that meets quality of the pharmaceutical preparations requirement in the preparation research to sodium tanshinone IIA sulfate.
Thereby the objective of the invention is to provides a kind of high-capacity injection that contains sodium tanshinone IIA sulfate new, safety for clinical, for clinical application provides a kind of new selection.
[summary of the invention]
Technical problem to be solved by this invention has provided a kind of high-capacity injection that contains sodium tanshinone IIA sulfate, and this injection meets the requirement of general injecting drug use, provides a kind of new medication to select for clinical.
The English name of sodium tanshinone IIA sulfate is: Sulfotanshinone Sodium.
Technology of the present invention realizes by following scheme:
The high-capacity injection that contains sodium tanshinone IIA sulfate of the present invention in every 1000ml injection, wherein contains: the sodium tanshinone IIA sulfate of effective dose and pharmaceutically acceptable adjuvant in the treatment.
The high-capacity injection that contains sodium tanshinone IIA sulfate of the present invention, in every 1000ml injection, wherein contain:
(a) sodium tanshinone IIA sulfate,
(b) sodium chloride,
(c) water for injection.
Preferably, the high-capacity injection that contains sodium tanshinone IIA sulfate of the present invention, in every 1000ml injection, wherein contain:
(a) sodium tanshinone IIA sulfate 10～4000mg
(b) sodium chloride 6～15g
(c) water for injection adds to 1000ml.
Preferred, the high-capacity injection that contains sodium tanshinone IIA sulfate of the present invention, in every 1000ml injection, wherein contain:
(a) sodium tanshinone IIA sulfate 40～1000mg
(b) sodium chloride 7～12g
(c) water for injection adds to 1000ml.
Further preferred, the high-capacity injection that contains sodium tanshinone IIA sulfate of the present invention, in every 1000ml injection, wherein contain:
(a) sodium tanshinone IIA sulfate 40～200mg
(b) sodium chloride 9g
(c) water for injection adds to 1000ml.
The high-capacity injection that contains sodium tanshinone IIA sulfate of the present invention wherein can also contain other pharmaceutically-active ingredients, and these pharmaceutically-active ingredients can play synergistic therapeutic action, or other pharmacological actions, as add cryptotanshinone, and the cardiovascular diseases is played synergistic therapeutic action, improve curative effect.
The high-capacity injection that contains sodium tanshinone IIA sulfate of the present invention wherein can also contain other acceptable accessories, as solubilizing agent, cosolvent, antioxidant, pH regulator agent, metal chelating agent etc.
Solubilizing agent that can list such as Tween 80 etc.; The cosolvent that can list is as 1,2-propylene glycol etc.; The antioxidant that can list such as sodium sulfite, sodium sulfite etc.; PH regulator agent such as sodium hydroxide, the hydrochloric acid etc. that can list; Metal chelating agent that can list such as EDTA-Na.
The high-capacity injection that contains sodium tanshinone IIA sulfate provided by the invention can prepare by the following method:
(a) get the sodium tanshinone IIA sulfate raw material that conforms to quality requirements, add proper amount of water for injection, stir and make medicine dissolution;
(b) sodium chloride of adding recipe quantity, stirring and dissolving;
(c) add an amount of active carbon, stir, absorption;
(d) coarse filtration is taken off charcoal, and benefit adds to the full amount of water for injection;
(e) with 0.22 μ m filtering with microporous membrane, fill is sealed, sterilization, promptly.
Injection of the present invention can be used glass bottle, also can be packed with the PVC that meets the drug packaging requirement.
The high-capacity injection that contains sodium tanshinone IIA sulfate of the present invention can adopt the mode medication of intravenous drip.For example, when the administration of human time spent, injection of the present invention, adult's dosage for each person every day can be 10mg～500mg, preferably 20mg～250mg.Can be once-a-day or multiple dosing, also can be administered once in many days.
The high-capacity injection that contains sodium tanshinone IIA sulfate of the present invention has good pharmaceutics performance, meets the requirement of intravenous injection medicine.
[specific embodiment]
Following embodiment further describes the present invention, but described embodiment only is used to illustrate the present invention rather than restriction the present invention.
Embodiment 1
The prescription (by 1000ml) that contains the high-capacity injection of sodium tanshinone IIA sulfate:
Sodium tanshinone IIA sulfate 10mg
Sodium chloride 15g
Water for injection is to 1000ml.
Get the sodium tanshinone IIA sulfate of recipe quantity, add 500ml water for injection, stirring and dissolving, the sodium chloride of adding recipe quantity, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 6.0～7.0, is heated to 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, coarse filtration is taken off charcoal, add water for injection to 1000ml, regulate pH value to 6.0～7.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 50ml, 100ml, 200ml, 250ml, 500ml, 1000ml for every bottle, seal, sterilized 20 minutes, and promptly got injection of the present invention for 115 ℃.
Embodiment 2
The prescription (by 1000ml) that contains the high-capacity injection of sodium tanshinone IIA sulfate:
Sodium tanshinone IIA sulfate 4000mg
Sodium chloride 6g
Water for injection is to 1000ml.
Get the sodium tanshinone IIA sulfate of recipe quantity, add 500ml water for injection, stirring and dissolving, the sodium chloride of adding recipe quantity, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 6.0～7.0, is heated to 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, charcoal is taken off in filter mutually, add water for injection to 1000ml, regulate pH value to 6.0～7.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 50ml, 100ml, 200ml, 250ml, 500ml, 1000ml for every bottle, seal, sterilized 20 minutes, and promptly got injection of the present invention for 115 ℃.
Embodiment 3
The prescription (by 1000ml) that contains the high-capacity injection of sodium tanshinone IIA sulfate:
Sodium tanshinone IIA sulfate 40mg
Sodium chloride 12g
Water for injection is to 1000ml.
Get the sodium tanshinone IIA sulfate of recipe quantity, add 500ml water for injection, stirring and dissolving, the sodium chloride of adding recipe quantity, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 6.0～7.0, is heated to 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, coarse filtration is taken off charcoal, add water for injection to 1000ml, regulate pH value to 6.0～7.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 50ml, 100ml, 200ml, 250ml, 500ml, 1000ml for every bottle, seal, sterilized 20 minutes, and promptly got injection of the present invention for 115 ℃.
Embodiment 4
The prescription (by 1000ml) that contains the high-capacity injection of sodium tanshinone IIA sulfate:
Sodium tanshinone IIA sulfate 1000mg
Sodium chloride 7g
Water for injection is to 1000ml.
Get the sodium tanshinone IIA sulfate of recipe quantity, add 500ml water for injection, stirring and dissolving, the sodium chloride of adding recipe quantity, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 6.0～7.0, is heated to 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, coarse filtration is taken off charcoal, add water for injection to 1000ml, regulate pH value to 6.0～7.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 50ml, 100ml, 200ml, 250ml, 500ml, 1000ml for every bottle, seal, sterilized 20 minutes, and promptly got injection of the present invention for 115 ℃.
Embodiment 5
The prescription (by 1000ml) that contains the high-capacity injection of sodium tanshinone IIA sulfate:
Sodium tanshinone IIA sulfate 100mg
Sodium chloride 9g
Water for injection is to 1000ml.
Get the sodium tanshinone IIA sulfate of recipe quantity, add 500ml water for injection, stirring and dissolving, the sodium chloride of adding recipe quantity, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 6.0～7.0, is heated to 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, charcoal is taken off in filter mutually, add water for injection to 1000ml, regulate pH value 6.0～7.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 50ml, 100ml, 200ml, 250ml, 500ml, 1000ml for every bottle, seal, sterilized 20 minutes, and promptly got injection of the present invention for 115 ℃.
Embodiment 6
The prescription (by 1000ml) that contains the high-capacity injection of sodium tanshinone IIA sulfate:
Sodium tanshinone IIA sulfate 100mg
Cryptotanshinone 50mg
Sodium chloride 8.5g
Tween 80 4g
Sodium sulfite 1g
Propylene glycol 20g
EDTA-Na 0.5g
Water for injection is to 1000ml.
Get sodium tanshinone IIA sulfate, cryptotanshinone, Tween 80, sodium sulfite, propylene glycol, the EDTA-Na of recipe quantity, add 500ml water for injection, stirring and dissolving, the sodium chloride of adding recipe quantity, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 6.0～7.0, is heated to 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, coarse filtration is taken off charcoal, add water for injection to 1000ml, regulate pH value to 6.0～7.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 50ml, 100ml, 200ml, 250ml, 500ml, 1000ml for every bottle, seal, sterilized 20 minutes, and promptly got injection of the present invention for 115 ℃.
Embodiment 7
The prescription (by 1000ml) that contains the high-capacity injection of sodium tanshinone IIA sulfate:
Sodium tanshinone IIA sulfate 100mg
Sodium chloride 8.5g
Tween 80 4g
Sodium sulfite 1g
Propylene glycol 20g
EDTA-Na 0.5g
Water for injection is to 1000ml.
Get sodium tanshinone IIA sulfate, Tween 80, sodium sulfite, propylene glycol, the EDTA-Na of recipe quantity, add 500ml water for injection, stirring and dissolving, the sodium chloride of adding recipe quantity, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 6.0～7.0, is heated to 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, coarse filtration is taken off charcoal, add water for injection to 1000ml, regulate pH value to 6.0～7.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 50ml, 100ml, 200ml, 250ml, 500ml, 1000ml for every bottle, seal, sterilized 20 minutes, and promptly got injection of the present invention for 115 ℃.
Embodiment 8
The prescription (by 1000ml) that contains the high-capacity injection of sodium tanshinone IIA sulfate:
Sodium tanshinone IIA sulfate 100mg
Sodium chloride 8.5g
Anhydrous sodium sulfite 1g
Propylene glycol 20g
EDTA-CaNa2 0.5g
Water for injection is to 1000ml.
Get sodium tanshinone IIA sulfate, anhydrous sodium sulfite, propylene glycol, the EDTA-CaNa2 of recipe quantity, add 500ml water for injection, stirring and dissolving, the sodium chloride of adding recipe quantity, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 6.0～7.0, is heated to 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, charcoal is taken off in filter mutually, add water for injection to 1000ml, regulate pH value to 6.0～7.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 50ml, 100ml, 200ml, 250ml, 500ml, 1000ml for every bottle, seal, sterilized 20 minutes, and promptly got injection of the present invention for 115 ℃.
Embodiment 9
The prescription (by 1000ml) that contains the high-capacity injection of sodium tanshinone IIA sulfate:
Sodium tanshinone IIA sulfate 100mg
Sodium chloride 8.5g
Sodium citrate 1g
EDTA-Na 0.5g
Water for injection is to 1000ml.
Get sodium tanshinone IIA sulfate, sodium citrate, the EDTA-Na of recipe quantity, add 500ml water for injection, stirring and dissolving, the sodium chloride of adding recipe quantity, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 6.0～7.0, heats 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, coarse filtration is taken off charcoal, add water for injection to 1000ml, regulate pH value to 6.0～7.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 50ml, 100ml, 200ml, 250ml, 500ml, 1000ml for every bottle, seal, sterilized 20 minutes, and promptly got injection of the present invention for 115 ℃.
Reference examples 1---sodium tanshinone IIA sulfate injection with small volume
With reference to the China national drug standard (product standard number: WS-10001-(HD-1014)-2002), the low capacity aqueous injection of preparation sodium tanshinone IIA sulfate.Prescription is by 1000ml:
Sodium tanshinone IIA sulfate 5g
EDTA-Na 0.5g
Water for injection is to 1000ml.
Get sodium tanshinone IIA sulfate, the EDTA-Na of recipe quantity, add 500ml water for injection, stirring and dissolving.Add 0.1% (w/v) active carbon, adding 1M hydrochloric acid solution or 1M sodium hydroxide solution adjusting pH value is 4.0～5.0, is heated to 70～80 ℃, stirred 10 minutes, and be chilled to 40～50 ℃, coarse filtration is taken off charcoal, add water for injection to 1000ml, regulate pH value to 4.0～5.0, with 0.22 μ m filtering with microporous membrane, fill, can adorn 2ml, 5ml, 10ml, 20ml for every bottle, seal, sterilized 20 minutes, and promptly got the sodium tanshinone IIA sulfate injection with small volume for 115 ℃.
Experimental example 1---contain the quality investigation of the high-capacity injection of sodium tanshinone IIA sulfate
Investigate sample: the sample of the sample of embodiment 1～embodiment 9 and reference examples 1.
Investigate index and method: appearance character and clarity, visible foreign matters, particulate matter, pH value, osmotic pressure, content (sodium tanshinone IIA sulfate, sodium chloride).
Appearance character and clarity: the appearance character of perusal sample and clarity.
Visible foreign matters: check (light scattering method) according to " two appendix IX of Chinese Pharmacopoeia version in 2000 H ".
Particulate matter: check (light blockage method) according to " two appendix IX of Chinese Pharmacopoeia version in 2000 C ".
PH value: measure according to " two appendix VI of Chinese Pharmacopoeia version in 2000 H ".
Osmotic pressure: the osmometry in two appendix of Chinese Pharmacopoeia version in 2005 is measured.
Content: the assay of sodium tanshinone IIA sulfate can carry out with reference to the method in the China national drug standard (WS-10001-(HD-1014)-2002).The assay of sodium chloride can carry out with reference to the content assaying method in Chinese Pharmacopoeia 2005 version " high-capacity injection ".
Result of the test sees Table 1.
From the table the result as seen, the main quality examination index of every injection of the sample of 9 embodiment of the present invention all meets the regulation of injecting drug use
The study on the stability that experimental example 2---low temperature keeps sample for a long time
With the sample of embodiment 1～embodiment 9, and the sample of reference examples 1, in 4 ℃ refrigerator, place and observed precipitation whether occurs in 6 months, the results are shown in Table 1.
As seen result from table makes sodium tanshinone IIA sulfate after the jumbo injection, and low temperature is placed and precipitation can not occurred, and precipitation can appear in injection with small volume.
Table 1 contains the quality investigation result of the high-capacity injection of sodium tanshinone IIA sulfate
| Sample | Appearance character and clarity | Visible foreign matters | Particulate matter | The pH value | Osmotic pressure (mOsM/kg) | Sodium chloride content (g/100ml) | Sodium tanshinone IIA sulfate content (mg/100ml) | 4 ℃ of solution appearance character and clarity of preserving after 6 months |
| Embodiment 1 | The pale red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 6.43 | 881.3 | 1.519 | 1.02 | The pale red clear liquid |
| Embodiment 2 | The pale red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 6.57 | 284.1 | 0.607 | 398.73 | The pale red clear liquid |
| Embodiment 3 | The pale red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 6.41 | 618.7 | 1.194 | 4.11 | The pale red clear liquid |
| Embodiment 4 | The pale red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 6.31 | 303.2 | 0.706 | 101.36 | The pale red clear liquid |
| Embodiment 5 | The pale red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 6.55 | 311.2 | 0.903 | 10.13 | The pale red clear liquid |
| Embodiment 6 | The pale red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 6.63 | 303.6 | 0.856 | 10.27 | The pale red clear liquid |
| Embodiment 7 | The pale red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 6.67 | 309.3 | 0.851 | 9.94 | The pale red clear liquid |
| Embodiment 8 | The pale red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 6.43 | 301.4 | 0.863 | 10.03 | The pale red clear liquid |
| Embodiment 9 | The pale red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 6.51 | 307.6 | 0.848 | 10.11 | The pale red clear liquid |
| Reference examples 1 | Red clear liquid | Do not detect visible foreign matters | Meet the pharmacopeia regulation | 4.41 | - | - | 503.11 | Red liquid has precipitation, smolders |
Claims (8)
1. a high-capacity injection that contains sodium tanshinone IIA sulfate wherein contains: the sodium tanshinone IIA sulfate of effective dose and pharmaceutically acceptable adjuvant in the treatment.
2. by the high-capacity injection of claim 1,, wherein contain in every 1000ml injection:
(a) sodium tanshinone IIA sulfate,
(b) sodium chloride,
(c) water for injection.
3. by the high-capacity injection of claim 2,, wherein contain in every 1000ml injection:
(a) sodium tanshinone IIA sulfate 10～4000mg
(b) sodium chloride 6～15g
(c) water for injection adds to 1000ml.
4. by the high-capacity injection of claim 3,, wherein contain in every 1000ml injection:
(a) sodium tanshinone IIA sulfate 40～1000mg
(b) sodium chloride 7～12g
(c) water for injection adds to 1000ml.
5. by the high-capacity injection of claim 4,, wherein contain in every 1000ml injection:
(a) sodium tanshinone IIA sulfate 40～200mg
(b) sodium chloride 9g
(c) water for injection adds to 1000ml.
6. by the high-capacity injection of claim 2, wherein also further contain other pharmacological component.
7. by the high-capacity injection of claim 2, wherein also further contain other pharmaceutically acceptable adjuvant, be selected from solubilizing agent, cosolvent, antioxidant, pH regulator agent, the metal chelating agent one or more.
8. by the preparation method of each described high-capacity injection of claim 1～7, comprising following steps:
(a) get the sodium tanshinone IIA sulfate raw material that conforms to quality requirements, add proper amount of water for injection, stir and make medicine dissolution;
(b) sodium chloride of adding recipe quantity, stirring and dissolving;
(c) add an amount of active carbon, stir, absorption;
(d) coarse filtration is taken off charcoal, and benefit adds to the full amount of water for injection;
(e) with 0.22 μ m filtering with microporous membrane, fill is sealed, sterilization, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510090489 CN1915230A (en) | 2005-08-17 | 2005-08-17 | Injection in large capacity of sodium sulfonate containing tanshinone IIA and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510090489 CN1915230A (en) | 2005-08-17 | 2005-08-17 | Injection in large capacity of sodium sulfonate containing tanshinone IIA and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1915230A true CN1915230A (en) | 2007-02-21 |
Family
ID=37736390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510090489 Pending CN1915230A (en) | 2005-08-17 | 2005-08-17 | Injection in large capacity of sodium sulfonate containing tanshinone IIA and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1915230A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885823A (en) * | 2012-10-23 | 2013-01-23 | 广东岭南制药有限公司 | Stable pharmaceutical composition containing sodium tanshinone IIA sulfonate |
-
2005
- 2005-08-17 CN CN 200510090489 patent/CN1915230A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885823A (en) * | 2012-10-23 | 2013-01-23 | 广东岭南制药有限公司 | Stable pharmaceutical composition containing sodium tanshinone IIA sulfonate |
| CN102885823B (en) * | 2012-10-23 | 2014-03-12 | 广东岭南制药有限公司 | Stable pharmaceutical composition containing sodium tanshinone IIA sulfonate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1304039C (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN1596882A (en) | Vitamin K1 emulsion and its freeze-dried emulsion and preparation method | |
| CN1915986A (en) | High purified tanshinone IIA sodium sulfonate, fabricating method, and preparation | |
| CN1686441A (en) | Chinese medicine capsule used for regulating immunity, its preparation method and use | |
| CN1861104A (en) | Inula flower extractive used to breat diabets mellitus and hyperlipidemia | |
| CN1915230A (en) | Injection in large capacity of sodium sulfonate containing tanshinone IIA and preparation method | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1248698C (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN1720948A (en) | Dripping pills of lllicium henryi dripping pills and method for preparing the same | |
| CN1748758A (en) | Dragon's blood gel preparation and its preparing method | |
| CN100350898C (en) | Diphase capsule of compound notoginseng and preparation method | |
| CN1210023C (en) | Carboplatin precursor liposome injection and preparing process thereof | |
| CN1626145A (en) | Medication for treating cough | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1586516A (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1747740A (en) | Analgesic composition | |
| CN1456198A (en) | Angong hemostatics | |
| CN101062040A (en) | Stable type cucurbitacin liquid formula and the agent thereof | |
| CN1271995C (en) | Orally disintegrating tablet of 'Xintongning' and its preparation | |
| CN101053598A (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN1895314A (en) | A lyophilized powder for injection containing Notoginseng radix total saponin with good appearance and shatter resistance, and its preparation method | |
| CN1582946A (en) | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1278705C (en) | Orally disintegrating tablet of 'Tongxinluo' and its preparation | |
| CN1686432A (en) | Earthworm drip pill and its preparation method | |
| CN1682821A (en) | Compound radical lobelia dripping pill and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: DOBORIPHY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ALBEILA MEDICINES HOLDINGS (TONGHUA) CO., LTD. Effective date: 20081031 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20081031 Address after: 66, Xiangjiang Road, Jilin, Meihekou Province, China: 135000 Applicant after: Duprofit Pharmacy Company Limited Address before: East section, North Ring Road, Meihekou economic and Trade Development Zone, Jilin Province, China: 135000 Applicant before: Aerbeila Pharmacy Holding Co., Ltd. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070221 |